Abstract: 【Abstract】 Cutaneous squamous cell carcinoma （cSCC） is the second most common skin malignancy. Early diagnosis, standardized treatment, and scientific prevention are of critical clinical significance. Histopathological examination remains the gold standard for its definitive diagnosis. Treatment strategies for cSCC vary according to disease stages. In recent years, systemic therapies such as immune checkpoint inhibitors have shown important progress in the management of high?risk cSCC, though clinical consensus has not yet been established. To integrate the latest evidence and improve clinical practice for cSCC, this guideline updates the “Consensus on diagnosis and treatment of cutaneous squamous cell carcinoma （2021）”. By incorporating recent advances in clinical research and relevant consensus recommendations from both Chinese and international sources, expert recommendations were formulated through the Delphi method. Key updates include standardizing the histopathological examination procedure, clarifying the indications for sentinel lymph node biopsy and lymph node dissection, and integrating the latest clinical data and application recommendations for immunotherapy, targeted therapy, and neoadjuvant therapy in cSCC. This guideline aims to provide evidence-based clinical guidance for the standardized diagnosis and treatment of cSCC in China, with the goal of improving the overall quality of care and patient outcomes.

Key words: Carcinoma, squamous cell, Therapeutics, Diagnosis, Practice guidelines, Skin, Recommendation